Last $49.46 USD
Change Today +0.14 / 0.28%
Volume 8.8M
BMY On Other Exchanges
Symbol
Exchange
New York
Mexico
Sao Paulo
Frankfurt
As of 6:40 PM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BMY) Snapshot

Open
$48.96
Previous Close
$49.32
Day High
$49.89
Day Low
$48.56
52 Week High
03/6/14 - $57.49
52 Week Low
08/22/13 - $41.11
Market Cap
82.0B
Average Volume 10 Days
6.4M
EPS TTM
$1.87
Shares Outstanding
1.7B
EX-Date
07/1/14
P/E TM
26.5x
Dividend
$1.44
Dividend Yield
2.89%
Current Stock Chart for BRISTOL-MYERS SQUIBB CO (BMY)

bristol-myers squibb co (BMY) Details

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The company’s principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products under Phase III clinical trials for treatment of cancer comprising Elotuzumab and Nivolumab. In addition, it develops Baraclude and Reyataz for pediatric extensions; Erbitux for esophageal cancer; Yervoy for melanoma, prostate cancer, and non-small-cell and small cell lung cancer; Orencia for lupus nephritis and psoriatic arthritis; and Eliquis for venous thromboembolic treatment and prevention. The company sells its products to wholesalers, and directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. It has strategic alliances with various third parties. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

28,000 Employees
Last Reported Date: 02/14/14
Founded in 1887

bristol-myers squibb co (BMY) Top Compensated Officers

Chief Executive Officer, Director, Member of ...
Total Annual Compensation: $1.7M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $901.1K
Chief Operating Officer and Director
Total Annual Compensation: $748.3K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: $736.1K
General Counsel and Corporate Secretary
Total Annual Compensation: $843.1K
Compensation as of Fiscal Year 2013.

bristol-myers squibb co (BMY) Key Developments

Bristol-Myers Appoints Jitendra Tyagi as India Head

Bristol-Myers Squibb Company announced the appointment of Jitendra Tyagi as the US drug maker's India head. He replaces Pheroze Khan and will be reporting to Michael Norman, its general manager for the Middle East, Africa and India. Tyagi joined Bristol-Myers Squibb in 2010 and has held various positions. Most recently, he was head of the Critical Care and Cardiovascular Business Unit. Tyagi was previously with Novartis, where he spent 21 years.

Bristol-Myers Squibb and Ono Pharmaceutical Co., Ltd. Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan

Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd. have signed a strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens to help address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan. As part of the agreement, Bristol-Myers Squibb and Ono will jointly develop and commercialize Opdivo (nivolumab) and Yervoy (ipilimumab) across a broad range of tumor types. Opdivo is a PD-1 immune checkpoint inhibitor approved in Japan for the treatment of patients with unresectable melanoma, making it the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world, and is being developed in multiple tumor types in more than 35 clinical trials. Yervoy, a CTLA-4 immune checkpoint inhibitor, is approved in Taiwan for the treatment of patients with advanced melanoma who have received prior therapy, and is in late-stage development as a potential treatment option for melanoma, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) in Japan. The agreement includes three additional early-stage clinical immuno-oncology assets from Bristol-Myers Squibb: lirilumab, an antibody that blocks the KIR receptor on natural killer cells, urelumab, an agonist of the CD137 co-stimulatory receptor, and BMS-986016, a LAG3 immune checkpoint inhibitor.

Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness and Safety of Eliquis(R) (apixaban) in Patients with NVAF Undergoing Cardioversion

Bristol-Myers Squibb Company and Pfizer Inc. announced that the first patient has been enrolled into a Phase IV clinical trial called EMANATE (Eliquis evaluated in acute cardioversion coMpared to usuAl treatmeNts for AnTicoagulation in subjEcts with NVAF) assessing the effectiveness and safety of Eliquis in patients with nonvalvular atrial fibrillation (NVAF) undergoing cardioversion. Eliquis is currently approved to reduce the risk of stroke and systemic embolism in patients with NVAF. Cardioversion (administered through electric shock to the chest or with medication) is a commonly used, effective method of converting atrial fibrillation to a normal rhythm, allowing the heart to pump more effectively. Traditionally, anticoagulation is administered for a minimum of three weeks prior to cardioversion and for four weeks afterward. In some patients, early cardioversion can be performed on the same day or within days of new-onset NVAF, usually after imaging, to confirm the absence of a pre-existing thrombus in the heart, which could be dislodged during the cardioversion procedure and cause a stroke. EMANATE, a randomized, open-label clinical trial, will assess the effectiveness and safety of Eliquis compared with usual care (parenteral heparin and/or oral anticoagulation with a vitamin K antagonist) initiated in patients with NVAF expected to undergo cardioversion after short-term anticoagulation, in a clinical practice setting. In NVAF patients presenting at least 48 hours after the onset of NVAF, early cardioversion will be performed after excluding a thrombus by imaging, on the same day or within a few days. In NVAF patients presenting within 48 hours of the onset of NVAF, cardioversion will be performed promptly without prior imaging. In all patients, Eliquis or usual care will be initiated prior to cardioversion and continued for up to 30 days post-cardioversion. The EMANATE trial is anticipated to enroll 1,500 eligible patients from the U.S., Canada, Europe and Asia. Patients will be randomized 1:1 to Eliquis or usual care, to be administered for up to 30 days following early cardioversion or 90 days post randomization if cardioversion is not performed within this timeframe. The primary efficacy endpoints are the occurrence of acute stroke, systemic embolism and all-cause death. Primary safety endpoints are major bleeding and clinically relevant non-major bleeding. ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMY:US $49.46 USD +0.14

BMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $54.08 USD -0.40
Amgen Inc $122.26 USD +0.25
Biogen Idec Inc $336.79 USD -0.81
Eli Lilly & Co $64.37 USD +0.12
Novo Nordisk A/S kr251.50 DKK -4.70
View Industry Companies
 

Industry Analysis

BMY

Industry Average

Valuation BMY Industry Range
Price/Earnings 28.4x
Price/Sales 5.0x
Price/Book 5.3x
Price/Cash Flow 28.3x
TEV/Sales 4.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRISTOL-MYERS SQUIBB CO, please visit www.bms.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.